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Abstract: 
Objective: To quantify the 6- and 12-month amputation-free survival (AFS) in patients with 
“no-option” Rutherford category 5/6 critical limb ischemia (CLI) in current clinical practice and 
to characterize outcomes and methods for deep vein arterialization as a possible means for 
revascularization in patients who are not candidates for conventional surgical or endovascular 
revascularization. We also sought to determine if there was any trend in amputation-free survival 
before and after 2003 which was the year of publication for the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC 7). 
Background: 
The natural history of patients with Rutherford category 5/6 CLI who are not candidates for 
revascularization is not well-known. Deep vein arterialization, or arterial shunting of blood to the 
deep veins, may offer a potential revascularization option for this select patient population.  
Methods: 
Data Sources and Study Selection  
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS  
A systematic review was performed according to PRISMA guidelines. Two pre-specified 
literature searches were conducted via Ovid utilizing the following databases: MEDLINE, 
EMBASE, and Cochrane Database of Systematic Reviews (CDSR). For the first literature 
search, we identified studies reporting AFS in patients with non-revascularizable Rutherford 
Category 5 or 6 CLI (or any symptomatic/ischemic equivalent) at a minimum follow-up of 6 
months. Studies that included a subset of patients with less severe disease (Rutherford Category 
≤4) were included. An exploratory search had determined that nearly all studies also included 
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Ruther category 4 patients. As such, a supplemental search was conducted to identify hazard 
ratios for amputation-free survival or its components between patients (regardless of 
revascularization status) with more severe (Rutherford Category 5/6), compared with less severe 
(Rutherford Category ≤4) disease to inform appropriate risk adjustment due to limited available 
outcome data in high risk patients. For the supplemental search, we selected studies of 
Rutherford category 4, 5, or 6 patients that reported hazard ratios (HR) for outcomes (AFS, all-
cause mortality, or major amputation) between high-risk (Rutherford 5/6) and lower-risk 
(Rutherford 4) patients. 
Deep Vein Arterialization 
A separate (third) systematic review was conducted via Ovid utilizing the following 
databases: MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews (CDSR). We 
identified prospective, randomized clinical trials as well as retrospective studies utilizing surgical 
or percutaneous deep vein arterialization (DVA) for revascularization of lower-extremity 
peripheral vascular disease. 
 
Data Extraction and Synthesis: 
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS  
Data was extracted from relevant articles in duplicate. Extracted information included qualifying 
CLI criteria, baseline demographics, enrollment dates, and proportion of patients with each 
Rutherford classification [(3) severe claudication; (4) ischemic rest pain; (5) minor tissue loss; or 
6 (major tissue loss)]or Fontaine stage [(IIa) mild claudication; (IIb) moderate severe 
claudication; (III) ischemic rest pain with or without minor tissue loss; (IV) ulceration or 
gangrene], and 6- and 12- month endpoints of interest (major amputation, defined as any 
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amputation performed above the level of the ankle, all-cause mortality, and amputation-free 
survival). Risk of bias of individual studies was assessed with the Cochrane Risk of Bias tool.  
Objective criteria such as the ability to complete standard treadmill exercise testing, ankle 
pressures before and after exercise, metatarsal peripheral vascular resistance, and toe pressures 
were used to impute the Rutherford categories of a study population if they were not directly 
reported. For studies that included a subset of lower-risk patients (Rutherford class ≤4), an 
adjustment factor was developed and applied to the observed rates to better reflect outcomes in 
the population of interest.  
An adjustment factor for AFS rates was calculated from the reported HRs by log 
transforming the HR, calculating the weighted average of the log HR, and inverting back to the 
arithmetic scale. The adjustment factor was then applied to the observed AFS rates in the 
applicable studies of no-option CLI patients according to the proportion of high-risk (Rutherford 
category 5/6) and low-risk (Rutherford category ≤4) patients in each study to arrive at an 
adjusted AFS rate 
Deep Vein Arterialization 
Data was extracted from relevant articles in duplicate for studies of deep vein arterialization in 
patients with CLI (Rutherford class 4 or higher or Fontaine stage III or higher). Extracted 
information included baseline patient demographics (Rutherford classification or Fontaine stage 
and comorbidities), peri-procedural outcomes (technical success rate, mortality, and 
complications within 30 days of procedure), medium-term outcomes (survival, limb salvage rate, 
cumulative patency, and mean follow-up time). 
 
Main Outcomes and Measures:  
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Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS  
Amputation-free survival (a composite of major amputation, defined as any amputation 
performed above the level of the ankle, and all-cause mortality) at 6- and 12-months in patients 
with Rutherford class 5 or 6 CLI and no revascularization options. Due to a scarcity of evidence, 
we collected HRs for any outcome (n=1 AFS; N=1 death; and N=1 major amputation). 
Deep Vein Arterialization 
Technical success, peri-procedural (within 30 days of procedure) mortality and 
complications, and postprocedural (>30 days postprocedure) survival, limb salvage (freedom 
from amputation in a threatened limb), and cumulative patency (freedom from any reintervention 
in the arterialized vein). 
 
Results:  
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS  
The meta-analytic adjustment factor for AFS rate at 6- and 12-months between Rutherford 4 
patients and Rutherford 5/6 patients was 2.18. A total of 36 studies meeting the selection criteria 
reported AFS at 6 and/or 12 months; the meta-analytic average AFS rates were 56.5% and 
49.8%, respectively. An analysis by time of enrollment determined that AFS was significantly 
higher at 6 and 12 months in studies enrolling patients after 2003 versus before 2003; therefore, 
analyses were limited to the recent (after 2003) cohort. The unadjusted meta-analytic average 
AFS rates at 6 and 12 months were 60.0% (n=23 publications; 1238 patients; 67.5% average 
Rutherford 5/6) and 56.1% (n=19 studies; 1161 patients; 57.7% average Rutherford 5/6), 
respectively. The risk-adjusted estimated AFS rates were 43.6% (95% CI, 33.7 – 53.5) at 6 
months (n=16 publications, 826 patients; 67.5% average Rutherford 5/6) and 36.8 (95% CI, 
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19.6-54.1) at 12 months (n=12 publications, 659 patients; 57.7% Rutherford 5/6) in no-option 
Rutherford category 5 or 6 CLI patients.  
Deep Vein Arterialization 
A total of 16 studies were identified reporting results for surgical DVA while 5 studies 
were identified reporting results for percutaneous (endovascular) DVA. We collected baseline 
patient comorbidities, Rutherford classification, Fontaine stage, peri-procedural outcomes 
(technical success, mortality, and complications) and medium-term outcomes (survival, limb 
salvage, cumulative patency).  
The average proportions of comorbidities in the surgical deep vein arterialization studies 
were 73% for diabetes, 60% for hypertension, 38% for hyperlipidemia, 54% for coronary artery 
disease, 28% for chronic renal disease, and 45% for current smokers. The average technical 
success rate for surgical deep vein arterialization was 81% with an average periprocedural (<30 
days) mortality of 2.4% and an average complication (<30 days) rate of 25%. The average 
technical success rate for percutaneous deep vein arterialization was 93% with an average 
periprocedural (<30 days) mortality of 0% and an average periprocedural (<30 days) 
complication rate of 16%. 
Conclusions and Relevance: Approximately half of all patients with advanced critical limb 
ischemia who are not candidates for current revascularization approaches will die or require 
major amputation within 1 year. These outcomes have not changed significantly in recent years, 
and alternative treatments that can address this high-risk population are urgently needed. 
Percutaneous deep vein arterialization is a promising technique for revascularization in patients 
with no other treatment options. 
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Abbreviations: 
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Introduction:  
Non-Option Critical Limb Ischemia 
Globally, over 200 million people were living with peripheral arterial disease (PAD) in 
2010, an increase of 13% over the previous decade in high-income countries and nearly 30% in 
low- and middle-income countries.(1) Approximately 10% of patients with advanced PAD have 
critical limb ischemia (CLI) defined as intractable foot pain at rest and/or tissue loss, which 
includes non-healing ulcers and gangrene.(2) Health care costs associated with CLI in the US 
exceeded $579 million in 2001 and increased to $870 million in 2007. A significant portion of 
these costs were driven by an increase in costs of procedures and an increased number of 
procedures. There is uncertainty whether this is due to an increase in the number of patients or an 
increase in the number of treatments per patient. (3) Despite numerous advances in endovascular 
and surgical revascularization techniques, revascularizable CLI is associated with a poor 
prognosis with a 50% mortality rate at 5-years and a quality of life comparable to that of patients 
with advanced stage cancer.(4-6) The estimated incidence of major amputation ranges from 120 
to 500 per million persons per year.(7) Diabetes mellitus increases the risk of amputation by 10 
fold and the prevalence of gangrene by 20-30 fold, compared with non-diabetic patients with 
CLI.(8,9)  
The Rutherford categorization is one of the most frequently used systems to classify CLI. 
(10) Rest pain (Rutherford 4), tissue loss (Rutherford 5) and/or gangrene (Rutherford 6) 
comprise the late stages of peripheral vascular disease. In the Fontaine classification system(11), 
rest pain (class III) and tissue loss or gangrene (class IV) are analogous to Rutherford category 4 
and Rutherford category 5/6, respectively. Only a small proportion, approximately 10%, of 
patients present with CLI despite the high prevalence of untreated PAD. Rest pain is usually 
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associated with multilevel disease, including both inflow (iliac, common femoral, or superficial 
femoral arteries) and outflow (tibial arteries) disease, whereas ischemic pain is caused by 
ischemia, areas of tissue loss, ischemic neuropathy or a combination of these and occurs or 
worsens with reduction of perfusion pressure. Ischemic pain can be alleviated by 
revascularization of inflow disease alone. (12,13) Some ulcers, which are a manifestation of 
Rutherford 5/6, are entirely ischemic in etiology while others have multifactorial causes (e.g. 
traumatic, venous, or neuropathic) and will not heal because of the severity of the underlying 
PAD. For patients with ulcers or gangrene, the presence of CLI is suggested objectively by an 
ankle pressure less than 70 mmHg or a toe systolic pressure less than 50 mmHg.(7) The 
significance of these measurements is that in most patients with ischemic lesions, resolution of 
lesions does not improve spontaneously without intervention. 
Revascularization options for CLI patients include endovascular, surgical, or hybrid 
(both) techniques.(14) However, because of advanced diffuse disease, severe co-morbidities, or 
anatomic limitations, approximately 40% of CLI patients are not candidates for conventional 
surgical or endovascular revascularization (“no-option” patients).(15,16) Little is known about 
the outcomes of patients with advanced (Rutherford category(10) 5 or 6 or Fontaine stage 
IV(11)) CLI who are not suitable for revascularization with currently available surgical or 
endovascular approaches. Outcomes for this patient population are rarely reported separately 
from patients with less severe disease. To address this knowledge gap, we performed a 
systematic review and a meta-analysis to estimate contemporary rates of amputation-free 
survival (AFS) in patients with severe Rutherford category 5/6 CLI who are not eligible for 
surgical or endovascular revascularization.  
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Systematic reviews and meta-analyses have become increasingly influential in health 
care. Clinicians often utilize systematic reviews and meta-analyses to stay current with their field 
and are often also used during the initial phases of development of clinical practice guidelines. 
(17,18) Prior to the development of the PRISMA (Preferred Reporting Items of Systematic 
reviews and Meta-Analyses), (19) an international group developed a guidance document called 
the QUORUM Statement (Quality of Reporting Meta-analyses), which was aimed to address the 
suboptimal quality of reporting of meta-analyses. The QUORUM Statement was primarily 
addressed to improve the quality of reporting of meta-analyses of randomized controlled trials. 
(20). In 2009, the QUORUM guideline was updated as the advancement in the science of 
systematic reviews resulted in several conceptual and practical advances in the field. The result 
was the publication of the PRISMA guidelines.(19) The PRISMA guidelines are generally 
regarded as the contemporary gold-standard for the conduction of systematic reviews and meta-
analyses. Thus, our systematic review and meta-analysis was conducted in accordance with these 
guidelines. 
Deep Vein Arterialization 
 A number of novel, experimental revascularization options in development such as total 
percutaneous bypass (21) or total percutaneous deep-vein arterialization (22) may offer safe and 
effective options to patients who otherwise have none.  
Deep vein arterialization is a particularly promising revascularization technique for 
patients who have long lesions that are unamenable to revascularization. An anastomosis is 
created between an inflow artery and an appropriate vein thereby reversing blood flow in the 
venous system. Reversal of blood flow allows for delivery of highly oxygenated blood to the 
distal foot. Valves in the veins must be rendered incompetent in order to allow for reversal of 
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blood flow.  Venous arterialization reestablishes direct flow to the foot based on the angiosome 
concept and aims to improve clinical outcomes. The angiosome concept refers to an anatomic 
unit of tissue (skin, subcutaneous tissue, fascia, muscle, and bone) fed by a source artery and 
drained by specific vein(s).(23) The technique was first performed through a surgical 
approach.(24) However, recent advances in catheter technology have allowed for an 
endovascular approach.(25) Whether the procedure is carried out through a surgical or 
endovascular approach the fundamental concepts remain the same despite the less invasive 
characteristics of an endovascular approach.  
 We sought to characterize the outcomes of deep vein arterialization in patients who had 
chronic CLI. Outcomes of interest included technical success, peri-procedural (within 30 days of 
procedure) mortality and complications, and postprocedural (>30 days postprocedure) survival, 
limb salvage, and cumulative patency.  
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Methods: 
This systematic review and meta-analysis was performed in accordance with PRISMA 
guidelines.(19) Briefly, the PRISMA guidelines includes a 27-item checklist for the conduction 
and reporting of a systematic review and meta-analysis.  
Contributions: 
I designed both literature searches and performed both literature searches. Abstracts and 
full-texts were screened by Daniela Tirziu (D.T.) and I (I.G.). I extracted all the data from 
relevant studies and assessed studies for risk of bias. Helen Parise (H.P.) carried out all statistical 
analyses of the data. I presented the work as an oral presentation at EuroPCR 2018 in Paris, 
France and as a moderated poster at TCT 2018 in San Diego, CA. 
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Literature Search: 
A prespecified literature search protocol was developed to identify data on clinical 
outcomes (at 6 months or later) of patients with non-revascularizable lower extremity critical 
limb ischemia. Because an exploratory search had determined that nearly all such studies also 
included Rutherford category 4 patients, a second search was performed to quantify the relative 
hazard of CLI patients classified as high risk (Rutherford category 5 or 6) in comparison with 
low risk (Rutherford category 4) patients for the outcomes of interest.  
The literature searches were conducted in November and December 2017 using Ovid 
(Wolters Kluwers, New York, NY) to search MEDLINE, EMBASE, and Cochrane Database of 
Systematic Reviews (CDSR) from inception to the date of the search. Abridged search terms and 
strategies are reported in the supplement (Supplemental Tables 1 and 2). 
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Study Selection: 
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS  
We selected randomized controlled trials, controlled trials without randomization, well-
designed cohort or case-control studies, longitudinal series, and case series. Studies reporting 
outcomes in patients with non-revascularizable lower extremity CLI and Rutherford Category 4, 
5, or 6 or any symptomatic/ischemic equivalent were included. Medical management, pain 
management, and wound care in accordance with non-experimental standard of care were 
permitted. Outcomes of interest were major (above the ankle amputation), amputation-free 
survival (AFS), and/or wound healing reported at a minimum follow-up duration of 6-months. 
For the supplemental search, we selected studies of Rutherford category 4, 5, or 6 
patients that reported hazard ratios (HR) for outcomes (AFS, all-cause mortality, or major 
amputation) between high-risk (Rutherford 5/6) and lower-risk (Rutherford 4) patients. Because 
no studies of no-option patients meeting these criteria were identified, the selection criteria were 
expanded to allow studies reporting HR between the groups of interest regardless of 
revascularization status with the assumption that the HR would be constant whether or not 
patients were revascularized.  
Two reviewers (I.G. and D.T.) independently screened titles and abstracts in duplicate; 
any discrepancies were resolved by consensus or by discussion with a third author (C.P.). Full-
text articles were obtained for those that met criteria in the initial screen of abstracts and titles 
were then further assessed for eligibility. The bibliographies of relevant articles were added to 
the systematic review with further screening and selection.  
Deep Vein Arterialization 
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 Two reviewers (I.G. and C.T.) independently screened titles and abstracts in duplicate; 
any discrepancies were resolved by consensus or by discussion with a third author (C.P.). We 
selected randomized controlled trials, controlled trials without randomization, well-designed 
cohort or case-control studies, longitudinal series, and case series. Studies reporting outcomes in 
patients with Rutherford category 4 or higher or Fontaine stage III with lower-extremity critical 
limb ischemia who underwent deep vein arterialization (percutaneous or surgical) were selected. 
There was no restriction on baseline Rutherford classification or Fontaine stage. Full-text articles 
were obtained for those that met criteria in the initial screen of abstracts and titles were then 
further assessed for eligibility. The bibliographies of relevant articles were added to the 
systematic review with further screening and selection. Outcomes of interest included technical 
success, peri-procedural (within 30 days of procedure) mortality and complications, and 
postprocedural (>30 days post-procedure) survival, limb salvage, and cumulative patency. 
 
Data Extraction and Risk of Bias Assessment: 
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS  
Two investigators (I.G. and D.T.) independently extracted data from the selected articles 
in duplicate. Any disagreements were resolved by consensus or with a third author (C.P.). We 
collected the number of patients, the number of limbs involved (when reported), number of 
centers involved in the study, dates of enrollment, qualifying CLI criteria (Rutherford class, 
Fontaine stage, or symptomatic equivalent [ischemic rest pain, tissue loss, ulcer, gangrene, ankle 
pressure <70 mm Hg, toe pressure <50 mm Hg, flat pulse volume recording, or transcutaneous 
oxygen pressure <40 mm Hg]), baseline patient demographics, proportion of patients with each 
severity class/stage or symptomatic equivalent, history of vascular interventions, wound 
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characteristics, and outcomes at 6- and 12-months (mortality, amputation, amputation-free 
survival, wound healing). 
Risk of bias of individual studies was assessed with the Cochrane Collaboration’s 
tool.(26) The Cochrane risk-of-bias tool for randomized trials is the recommended tool to assess 
the risk of bias in randomized trials included in Cochrane Reviews. Judgements on risk of bias of 
included studies are made based on a series of questions in the tool. Studies were assessed on the 
basis of sequence generation, allocation concealment, blinding, incomplete outcome data, 
selective reporting, and other sources of bias. Blinding and randomization were not performed in 
all studies. 
Deep Vein Arterialization 
 Two investigators (I.G. and P.B.) independently extracted data from the selected articles 
in duplicate. Any disagreements were resolved by consensus or with a third author (C.P.). We 
collected the number of study sites, number of lower extremity limbs involved, settings 
(retrospective or prospective study or clinical trial), technical success rate, peri-procedural 
outcomes (30-day mortality or complications, pre- and post-procedure transcutaneous O2 
pressures), and medium-term outcomes (survival, limb salvage rates, and cumulative patency 
rates at >30 days). 
Data Synthesis and Statistical Analysis: 
Data tables for all included studies were compiled which included number of subjects, 
event-free survivors, AFS rate, included Rutherford classifications, proportion of patients with 
Rutherford 5/6 (or symptomatic equivalent) disease, and enrollment end dates. If the enrollment 
end date was not reported for a study, it was imputed based on date of manuscript submission or 
publication (first available). For studies that did not report the proportion of patients in each 
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Rutherford category, the proportion of high-risk (Rutherford 5/6) patients was imputed based on 
the average of all studies that reported this proportion as a best estimate of the prevalence in the 
population. 
As an initial analysis, overall AFS rates at 6 and 12 months were calculated by taking the 
meta-analytic average using inverse variance weighting and a random effects approach to 
account for the variability in the estimates and the potential heterogeneity of the studies. 
To determine whether there were significant changes in AFS event rates over time (e.g., due to 
improved medical management) that may affect the generalizability of the study results to 
current clinical practice, an analysis of AFS by time of enrollment was performed with a cut-off 
of 2003 which coincides with the publication of JNC 7 guidelines.(27) A chi-squared test was 
used to compare weighted averages for significant changes in AFS rates over different 
enrollment periods; a statistically significant difference in AFS rates by period of enrollment was 
used to establish a cutoff, with subsequent analyses considering only more recent studies. 
Finally, because most studies reporting amputation-free survival in no-option CLI patients 
included lower-risk subjects (Rutherford category 4), an adjustment factor was developed to 
better-fit available historical data to the population of interest. Hazard ratios (HR) for outcomes 
(AFS, all-cause mortality, or major amputation) between high-risk (Rutherford 5/6) and lower-
risk (Rutherford 4) patients were extracted from studies identified in the second literature search. 
An adjustment factor for AFS rates was calculated from the reported HRs by log transforming 
the HR, calculating the weighted average of the log HR, and inverting back to the arithmetic 
scale. The adjustment factor was then applied to the observed AFS rates in the applicable studies 
of no-option CLI patients according to the proportion of high-risk (Rutherford category 5/6) and 
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low-risk (Rutherford category ≤4) patients in each study to arrive at an adjusted AFS rate for 
each study according to the following formula:  
Adjusted AFS = (High Risk % × High Risk AFS) + (Low Risk % × Low Risk AFS)   
Where Low Risk AFS = Adjustment Factor × High Risk AFS 
A meta-analytic average of the adjusted AFS rates was then calculated using inverse variance 
weighting and a random effects approach to account for the variability in the estimates and the 
potential heterogeneity of the studies; 95% confidence intervals around the meta-analytic 
average adjusted AFS rate were also calculated. 
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Results: 
Study Characteristics 
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS 
Two tables with all studies included in the meta-analysis are included in the supplemental 
material (Supplemental Tables 4 and 5). A total of 1353 studies were identified through our 
literature search. After removing duplicates, a total of 1142 studies were screened at the level of 
titles and abstracts. A total of 1089 studies were irrelevant according to the literature search 
protocol. We assessed 53 full-text studies for eligibility. A total of 36 studies reported mortality, 
major amputation, or AFS at 6 or 12 months. No unpublished data were obtained or used in the 
meta-analysis. A flow diagram outlining the primary literature search results is depicted in 
Figure 1. For all studies reporting 6-month AFS, 61% (14/23) reported baseline Rutherford 
category (Supplemental Table 4), while 32% (6/19) of studies reporting 12-month AFS reported 
baseline Rutherford category (Supplemental Table 5). 
The supplemental literature search undertaken for the purposes of risk adjustment 
identified 495 results. After removing duplicates, non-English, and non-Human studies, we 
screened 287 studies at the abstract and title level. We identified 13 articles that were assessed at 
the full-text level. A total of 10 articles were deemed ineligible with reasons (n=8 did not report 
HR for desired comparisons; n=1 reported only a multivariate HR; n=1 duplicate patient 
population), resulting in a total of 3 studies from our supplementary search that reported 
unadjusted hazard ratios for subjects with Rutherford category 4 versus Rutherford category 5 
and/or 6. A complete flowchart for the supplemental literature search is provided in the 
Supplemental Figure 1. The individual study characteristics are reported in Table 2. Two studies 
reported baseline Rutherford category for patients enrolled in the study while one study did not. 
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Deep Vein Arterialization 
A comprehensive literature search identified 15 primary research articles presenting clinical data 
on venous arterialization for patients with lower extremity limb ischemia.  A variety of surgical 
techniques were utilized for deep vein arterialization (DVA). However, the principles remain the 
same. An arteriovenous fistula (AVF) is created between the most distal unobstructed artery and 
the most appropriate deep vein based on the angiosome model. Graft materials used for AVF 
creation have included the (great or short) saphenous vein, cephalic vein, or synthetic 
polytetrafluoroethylene (PTFE) grafts. Synthetic grafts may or may not be interposed with 
autologous vein material. Commonly used inflow arteries included the common femoral artery, 
superficial femoral artery, and the popliteal artery. Common venous targets for distal 
anastomosis included the posterior tibial veins, anterior tibial veins, peroneal veins, dorsal 
venous arch, plantar venous arch, medial marginal veins, and pre-malleolar saphenous vein. 
Valvulotomy was often performed to destroy competent valves for complete venous 
arterialization. The most commonly used device for valvulotomy was the LeMaitre Valvulotome. 
In order to maintain blood pressure for distal delivery, collaterals are ligated surgically or 
embolized with devices. 
 
Quality of Evidence: 
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS 
The quality of study design and potential risk for bias for the included studies is included 
in the supplement (Supplemental Table 6). A total of 27 studies were assessed for risk of bias 
according to PRISMA guidelines (19). Some studies had high-risk of bias due to either random 
sequence generation, allocation concealment, blinding of participants and personnel, and 
22 
 
blinding of outcome assessments. No studies were at high-risk for incomplete outcome data or 
selective reporting.  
Random sequence generation was at low-risk of bias for 21 studies. There were no 
studies with uncertain risk of bias for random sequence generation. Allocation concealment was 
at low-risk of bias for 18 studies. Blinding of participants and personnel was at low-risk of bias 
for 16 studies with uncertain risk for 3 studies. Blinding of outcome assessment was at low-risk 
of bias for 16 studies with 5 studies at uncertain risk. All studies were at low-risk for incomplete 
outcome data with only one study at uncertain risk. No studies were at high-risk for selective 
reporting. A total of 5 studies were at uncertain risk for other bias with the rest at low-risk for 
uncertain bias. 
Deep Vein Arterialization 
 Averages and weighted averages were calculated for peri-procedural outcomes (technical 
success, mortality, and complications at <30 days) and medium-term outcomes (survival, limb 
salvage, cumulative patency) at >30 days post-procedure. 
 
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS 
Overall AFS Event Rates and Temporal Trends 
Overall, the unadjusted meta-analytic average AFS rate in all identified studies was 
56.5% at 6 months and 49.8% at 12 months. An analysis by time of enrollment determined that 
AFS was significantly higher in studies enrolling patients after 2003 for both 6-month (N=14 
publications; 740 patients) and 12-month (N=13 publications; 698 patients) compared with AFS 
before 2003 for 6-months (N=9 studies; 498 patients) and 12-months (N=6 studies; 215 patients) 
(weighted averages at 6 months: 72.8% vs. 47.0%, P<0.0001 and at 12 months: 62.2% vs. 
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46.4%, p<0.0001) (Table 1). There was no statistically significant difference at 6 or 12 months 
when studies reporting AFS were grouped into those ending enrollment between 2003-2010 
compared to those ending in 2010 and later. Therefore, subsequent analyses, specifically the risk 
adjustment analysis, adjusted for baseline Rutherford class consider only studies with enrollment 
ending in 2003 and later. For 6-month AFS there were 16 studies with 826 patients and for 12-
month AFS there were 12 studies with 659 patients. 
 
Natural History of “no-option” Rutherford category 5/6 CLI: 6- and 12-month AFS 
Risk-Adjusted AFS Rates  
Using the methods described above and the unadjusted hazard ratios from Table 2, a 
meta-analytic adjustment factor for AFS rate between Rutherford 4 patients and Rutherford 5/6 
patients of 2.18 was obtained and applied to the 6- and 12-month AFS rates reported in studies 
ending in 2003 or later to arrive at a risk-adjusted estimated event rates in the population of 
interest. 
Adjusted and unadjusted 6- and 12-month AFS rates for each study, along with relevant 
population characteristics are summarized in Tables 3 and 4. Of the studies reporting 6-month 
AFS rates, 50% (8/16) reported baseline Rutherford category, and for studies reporting 12-month 
AFS rates, 50% (6/12) reported baseline Rutherford category. A total of 8 studies reporting 6-
month AFS, and 6 studies reporting 12-month AFS, did not report baseline Rutherford category 
and therefore an imputed value based on the average of studies that did report baseline status was 
used. The average proportion of Rutherford 5/6 patients was 67.5% for 6-month AFS studies and 
57.5% for 12-month AFS studies.  
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The unadjusted meta-analytic estimate for 6-month AFS in studies ending enrollment 
after 2003 was 60% (95% CI, 48.5-71.5), and was 56.1% (95% CI, 34.4-77.9) at 12 months. 
After risk-adjustment, the meta-analytic estimate for the contemporary rate of AFS at 6 months 
in no-option patients with Rutherford category 5 or 6 CLI was 43.6% (95% CI, 33.7-53.5) and 
was 36.8% (95% CI, 19.6-54.1) at 12 months. Figure 2 depicts adjusted 6-month AFS rates 
according to trial size, imputed or reported baseline Rutherford category and last date of 
enrollment. Figure 3 depicts adjusted 12-month AFS rates according to trial size, imputed or 
reported baseline Rutherford category and last date of enrollment. 
Deep Vein Arterialization 
Data Source and Patient Characteristics 
Supplemental Table 6 presents a list of the search terms that were used to identify studies 
in OVID.  Table 5 presents study characteristics for studies reporting surgical venous 
arterialization and Table 6 presents study characteristics for studies reporting endovascular 
venous arterialization. Patients undergoing venous arterialization all had Rutherford 5/6 or 
Fontaine III/IV critical limb ischemia with the exception of one study for surgical venous 
arterialization which included Rutherford 4 patients. Reported comorbidities included diabetes, 
coronary artery disease, end-stage renal disease (ESRD), cerebrovascular disease, COPD, 
hypertension and obesity. Table 7 presents patient characteristics in studies reporting surgical 
venous arterialization: diabetes (73% average, 72% weighted average), hypertension (60% 
simple average, 58% weighted average), hyperlipidemia (38% simple average, 33% weighted 
average), coronary artery disease (54% simple average, 33% weighted average), chronic renal 
disease (28% simple average, 29% weighted average), and current smokers (45% simple 
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average, 30% weighted average). Table 8 presents patient characteristics in studies reporting 
endovascular venous arterialization. 
 
Peri-Procedural Outcomes: 
Peri-procedural outcomes for surgical deep vein arterialization (DVA) are presented in 
Table 8 below. Technical success rates ranged from 73% to 93% with an average of 81% and a 
weighted average of 80%. Peri-procedural mortality rates ranged from 0% to 7% with an average 
of 2.4% and a weighted average (weighted by number of patients) of 2.6%. The rate of any peri-
procedural complication ranged from 14% to 47% with an average of 25% and a weighted 
average of 27%.   
Mortality rates were low in studies reporting surgical deep venous arterialization. In one 
case series of 13 patients (14 limbs) there was one periprocedural death.(28) In another 
retrospective series, there was one periprocedural death (6%) in a patient with early graft failure 
within 21 days requiring amputation. In a prospective study of 26 patients, there was one (4%) 
peri-procedural death from pneumonia with respiratory failure.(29) There was one in-hospital 
death (5%) in a retrospective series of patients undergoing surgical vein arterialization compared 
to a group undergoing pedal bypass. One patient (7%) died from myocardial infarction in a 
retrospective single center study with 14 patients (15 limbs) undergoing deep vein arterialization. 
Peri-procedural outcomes for percutaneous (endovascular) deep vein arterialization are 
presented below in Table 9. Pre- and post-procedure transcutaneous O2 (TcPO2), mortality, and 
complications were reported for most studies. The average technical success rate for 
percutaneous deep vein arterialization was 93% with no peri-procedural mortality reported and 
an average complication rate of 16%. 
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Medium-term Outcomes (>30 days) 
Medium-term outcomes for surgical deep vein arterialization (DVA) are presented in 
Table 10 below and include survival, limb salvage, and cumulative patency reported >30 days 
post-procedure. Due to significant heterogeneity in timepoints of reported outcomes, no averages 
were calculated. Survival at 12-months ranged from 85-100% while 12-month limb salvage 
rates, defined as freedom from amputation in a threatened limb, ranged from 57-100% and 
cumulative 12-month primary patency, defined as freedom from any reintervention in the 
arterialized vein, ranged from 59-66%. Due to the lack of robust clinical data, there were no 
predictors of survival reported in the referenced studies. In one prospective randomized clinical 
trial comparing surgical deep vein arterialization with conservative medical therapy, the survival 
rates were 97% and 67%, respectively (P<0.001). 
Medium term outcomes from studies with percutaneous deep vein arterialization are 
presented in Table 11 below. Survival ranged from 57-100% with limb salvage rates ranging 
from 56-100%. Cumulative patency was not reported in any studies. Predictors of survival were 
not reported. 
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Discussion 
This is the first systematic review and meta-analysis of outcomes for patients with 
Rutherford category 5/6 critical limb ischemia who were poor candidates for conventional 
surgical or endovascular revascularization approaches. There are several important conclusions 
from our study. The most relevant finding is the low rates of AFS in this population; more than 
50% of patients with Rutherford 5/6 who are not candidates for revascularization will either lose 
a limb or die within 1 year. The implications are sobering given that the prevalence of critical 
limb ischemia can only be expected to rise with current increasing life expectancy, prevalence of 
diabetes, obesity, and sedentary lifestyles.(1,30)  
Despite these dismal statistics, the second observation that no-option CLI patients enrolled 
before 2003 had even worse outcomes compared to those enrolled after 2003 likely speaks to the 
impact of changes in secondary prevention guidelines and the introduction of new therapies for 
lipid lowering, blood pressure control, smoking cessation(31)  as well as no smoking laws that 
became wider-spread in 2004.  A study of lipid levels in US adults found a favorable trend from 
1988-2010 likely attributable to increased usage of lipid-lowering medications and a decrease in 
consumption of trans-fatty acids. (32) 2003 marked the release of the JNC-7 hypertension 
management guidelines,(27) likely indicating that improved approaches to risk factor 
management may have contributed to the observed temporal differences.   
The current TASC II (Trans-Atlantic Inter-Society Consensus Document on Management 
of Peripheral Arterial Disease) guidelines are used to determine management of patients with 
CLI. Once CLI is confirmed, if patients are candidates for revascularization they may undergo 
imaging to further characterize disease. Imaging methods include Duplex angiography, Magnetic 
Resonance Angiography (MRA), and CT angiography (CTA). Patients may then be 
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revascularized as appropriate.(12) The TASC II guideline recommends intensified medical 
management for all patients with peripheral arterial disease including smoking cessation, weight 
reduction, lipid lowering, antihypertensives, diabetic control, and antiplatelet therapy.  
Endovascular techniques such as percutaneous transluminal angioplasty (PTA) are the preferred 
treatment for limited infrainguinal disease (stenoses/occlusions up to 10 cm in length). 
Endovascular treatment is also indicated for infrapopliteal limb salvage. Anatomic 
considerations must be taken into account when selecting patients for infrainguinal surgical 
bypass along with considerations for conduit. With the limitations in indications for surgical or 
endovascular revascularization, some patients may not be candidates for either conventional 
approach. The recommended treatment options for no-option CLI are limited with no clear gold 
standard for these patients and poor outcomes regardless of management.  
In patients who are not candidates for revascularization, patients with stable pain and 
lesions may undergo non-operative medical management. Amputation is indicated for patients 
with non-tolerable pain or spreading infection.  
Though major amputation, all-cause mortality, and amputation-free survival are 
significant patient-oriented outcomes, pain control was not captured in this study. Indeed, pain 
management is essential in improving function and quality of life. Inconsistent use and reporting 
of standardized pain and quality of life scales limited our ability to quantify pain in this 
systematic review and meta-analysis. Pain management in patients with Rutherford category 5/6 
CLI is essential to improving function and quality of life. Pain is generally located to skin and 
possibly bone structures. Regardless of revascularization status, adequate pain control is essential 
for patients with CLI. All patients with CLI should have pain severity assessments to ensure 
adequate pain relief. Acetaminophen or nonsteroidal anti-inflammatory medications can be used 
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for initial management, but narcotic medications are indicated if pain is inadequately controlled. 
For patients who are not candidate for revascularization, narcotic pain relief is recommended by 
the TASC II guidelines. In patients with renal insufficiency or hypertension, caution must used 
when using narcotics. Pain medications should be used regularly to manage pain as on-demand 
use of pain medications may not adequately control pain. Concomitantly, placement of the limb 
in a dependent position with the foot of the bed tilted downward may assist with analgesia. 
Finally, patients with CLI often have mental health comorbidities in the form of depression. Pain 
control can be combined with antidepressant medications and may provide added benefit in those 
patients with depression. (12) 
Local ulcer care and pressure relief is also essential to management of patients with CLI 
regardless if revascularization is planned or not. Ulcers may be treated with a non-adherent 
gauze and should be off-loaded if there is an increase in pressure or shear stress. There are 
several methods that can be utilized for off-loading of ulcers including shoe modifications, 
orthotics and casting techniques. (33-35) The basic principles of ulcer care include removal of 
necrotic/fibrotic tissue from ulcers, keeping a moist wound environment and eliminating 
infection. 
Local infection is a life-threatening complication of neuroischemic ulcers with a severe 
course that should be treated urgently. Elevations of systemic inflammatory markers such as C-
reactive protein are uncommon. Early infection identification and assessment of local 
involvement is paramount to optimal outcomes. Infections should be treated aggressively with 
antibiotics. In diabetic patients, severe foot infections are generally polymicrobial with anaerobic 
organisms, gram negative rods, and gram positive cocci.(36) As such, broad spectrum antibiotics 
should be started urgently following wound culture to identify the causative micro-organisms. 
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Antibiotics can be narrowed once culture results and sensitivities become available. A rise in the 
incidence of multi-drug resistant Staphylcoccus aureus is a growing concern with an incidence of 
up to 30% in certain studies. Deep infections may also be managed with incision and drainage of 
necrotic tissue. Therapy with antibiotics is crucial for the prevention of further spread of 
infection.  
In addition to pain and ulcer management, glycemic control should be optimized for 
patients with diabetes mellitus. The health status of diabetic patients with CLI is generally poor. 
Diabetic control should accompany optimization of cardiac function and nutritional status.  
With all factors for CLI care considered, the TASC II guidelines recommend a multidisciplinary 
approach for care of patients with CLI.(12) This includes ulcer and pain management along with 
treatment of comorbidities such as depression. Additionally, control of diabetes must be carefully 
managed alongside other conditions such as cardiac conditions and poor nutritional status.(37) A 
multidisciplinary team with specialists can allow for a focus on limb preservation with 
significant improvement in outcomes and a reduction in the rates of lower extremity limb 
amputation. 
Therapeutic options for patients with no-option CLI remain limited. A recent meta-
analysis of RCTs found bone marrow derived cell therapy provided no benefit for amputation, 
survival or amputation free survival in patients with CLI.(38) The studies included in the meta-
analysis were small in size, mostly pilot studies, and insufficiently powered for therapeutic 
efficacy. Intermittent pneumatic compression (arterial flow pump) has been shown in single-
center retrospective registries to reduce amputation rates in patients without revascularization 
options; however, the quality of evidence is poor.(39)   
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Nevertheless, despite optimal medical therapy, current outcomes remain dismal and 
emphasize the clinical need for novel therapeutic approaches. Retrograde access, transcollateral 
recanalization, and pedalplantar loops techniques have provided successful options in patients 
with failed revascularization. (40-42) Still, 40% of CLI patients are not candidates for 
conventional surgical or endovascular revascularization.(15,16) Novel revascularization options 
in the pipeline that allow for total percutatneous bypass (21) or total percutaneous deep-vein 
arterialization (22) may offer safe and effective options to patients who otherwise have none. 
Effective pharmacologic interventions for smoking cessation started to arise in the late 
1990s/early 2000s.(31) Similarly, the Heart Outcomes Prevention Evaluation Study published in 
2000 highlighted the importance of angiotensin-converting-enzyme inhibitors for secondary 
prevention in patients with an ankle-brachial index value of <0.90.(43) In 1996, the results of the  
Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial led to FDA 
approval of clopidogrel for the secondary prevention of atherosclerotic events in patients with 
atherosclerosis, including those with peripheral arterial disease.(44) In a study of Danish 
nationwide administrative registries, antiplatelet use increased from 29% to 59% from 2000 to 
2007 (P<0.0001) while statin usage increased from 9% to 56% during the same time frame 
(P<0.0001).(45) Finally, 2003 marked the publication year of the JNC-7 hypertension 
management guidelines,(27) indicated that improved approaches to risk factor management may 
have contributed to the observed temporal differences.  
The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) 
trial randomized subjects with stable atherosclerotic vascular disease to low-dose rivaroxaban 
plus aspirin, rivaroxaban, or aspirin.(46) Peripheral arterial disease was defined as previous 
lower extremity revascularization, previous limb or foot amputation for arterial vascular disease, 
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history of intermitted claudication with 1 or more objective criteria, or previous carotid 
revascularization or asymptomatic carotid artery stenosis. Major adverse limb events, defined as 
severe limb ischemia leading to an intervention or major vascular amputation, occurred in 128 
patients. In a secondary analysis, subjects who suffered a major adverse limb event the 
subsequent 1-year cumulative risk for vascular amputations was 22.9%, for death 8.7%, and for 
major adverse cardiovascular events (MACE) 3.8%.(47) Our estimates for 6- and 12-month 
amputation-free survival in a higher-risk population of Rutherford category 5/6 patients are 
aligned with results from the sub-analysis of the COMPASS trial. The improved cardiovascular 
outcomes assigned to low-dose rivaroxaban and aspirin in the COMPASS trial also highlight a 
continued temporal trend for improved outcomes for patients with atherosclerotic vascular 
disease. 
 The field of percutaneous deep vein arterialization may benefit from a set of standardized 
outcomes and reporting measures to facilitate comparisons between devices and procedures. 
Indeed, in our literature search, there was high variability in the timepoints of reported outcomes 
and in the outcomes that were reported. Major amputations, all-cause mortality, graft patency, 
primary and secondary patency rates may be outcomes of interest when developing a guideline 
for the reporting of outcomes in this field. 
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Limitations: 
Our systematic review and meta-analysis has several limitations. Sample sizes in the 
identified studies were generally small, and definitions and classifications of critical limb 
ischemia and the clinical and anatomic determinants of unsuitability for revascularization varied. 
Variability in standards of care may have also varied as the studies included in our systematic 
review and meta-analysis spanned not only a large time period but also a wide geographical 
region. Due to incomplete reporting of enrollment dates and the proportion of patients in each 
risk category, some missing values had to be imputed based on best available information.  
Inherent to any systematic review and meta-analysis is the lack of external validity. 
Further validation of our results in a single-center study or multi-center study are necessary for a 
more precise and accurate assessment of this patient population.  
Several studies did not report baseline status of CLI based on either the Rutherford or 
Fontaine classification system or based on another objective or subjective characteristic. For this 
reason, we were required to make imputations for several studies. In studies that did not report 
baseline CLI status according to the Rutherford or Fontaine classification system, we limited our 
selected studies to those reporting baseline clinical characteristics such as rest pain, tissue ulcers, 
or tissue necrosis. Only one study that was included had Rutherford category 3 patients. 
However, the outcomes from this study were adjusted to account for this by the use of the 
adjustment factor. Given the limitations of the literature, we believe that the use of an adjustment 
factor provides a reasonable estimate for the outcomes of the patient population of interest. 
Newer classification systems, such as the Society for Vascular Surgery Lower Extremity 
Threatened Limb Classification: Risk stratification based on Wound, Ischemia, and foot 
Infection (WIfI) may provide improved prognostic value in high-risk patients.(48) However, 
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these measures were not reported in our source data, and challenges remain including selection 
of the appropriate hemodynamic cutoffs(49,50) and infrequent reporting of ankle-brachial 
indexes (ABIs) in clinical settings.(51) Furthermore, the WIfI classification system has not yet 
been validated in a large external dataset. Finally, our primary outcome of AFS does not align 
with recent recommendations from the Society of Vascular Surgery CLI Working Group for 
endpoints in a population of patients with CLI,(52) although the relevance of the composite 
major adverse limb events (which includes reintervention and early intervention-related 
complications) is inherently limited in the no-option patient population presented in this report. 
A pragmatic, validated limb ischemia classification system would provide significant benefit to 
clinicians who are assessing patients and would provide utility in determining which patients 
would benefit most from revascularization. 
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Conclusions: 
Our study emphasizes the especially poor outcomes for patients with advanced critical 
limb ischemia who are not candidates for currently available endovascular or surgical 
revascularization approaches. Given the increasing prevalence of peripheral vascular disease and 
critical limb ischemia, new approaches to enable revascularization in this high-risk population 
are sorely needed.  
The natural history of this selected patient population is difficult to study largely due to 
the preference for patients presenting with CLI to undergo revascularization if possible. Still, this 
study provides a reasonable estimate of the 6- and 12-month survival for late stage CLI that is 
not treatable by surgical or endovascular revascularization. Initial results suggest percutaneous 
deep vein arterialization may be a viable alternative in patients who are not candidates for 
standard revascularization.  
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Figure Legends 
Figure 1. Flow Diagram of Systematic Literature Search for the Meta-analysis 
Figure 2. Risk-adjusted 6-month AFS Rates in patients with no-option CLI. Size of plotted 
point correlates with cohort size while color correlates with proportion of imputed Rutherford 
category 5/6 (R5/6) subjects 
Figure 3. Risk-adjusted 12-month AFS Rates in patients with no-option CLI. Size of plotted 
point correlates with cohort size while color correlates with proportion of imputed Rutherford 
category 5/6 (R5/6) subjects 
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  N (Studies) Events (n) N (Total) Weighted Average P-value 
6-month AFS (Pre- and Post-2003) 
AFS pre 
2003 
9 234 498 47.00%   
AFS 2003+ 14 539 740 72.80%   
Total 773 1238 62.40% <0.0001 
6-month AFS (2003-2010 vs 2010 and later) 
AFS pre 
2010  
6 407 578 70.40%   
AFS 2010+  10 169 248 68.10%   
Total  576 826 69.70% 0.5151 
12-month AFS (Pre- and Post-2003) 
AFS pre 
2003 
6 215 463 46.40%   
AFS 2003+ 13 434.5 698 62.20%   
Total 649.5 1161 55.90% <0.0001 
12-month AFS (2003-2010 vs 2010 and later) 
AFS pre 
2010  
5 319 506 63.00%   
AFS 2010+  7 98 153 64.10%   
Total  417 659 63.30% 0.8206 
Table 1. Analysis of AFS Trend by Period of Enrollment 
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Study N Patient 
Risk 
Profile 
Variable Event Unadjusted 
Hazard 
Ratio 
95% 
CI 
R4  
n  
(%) 
R5 n 
(%) 
R6 n 
(%) 
Chung 
et al. 
2013 
(53) 
98 Rutherford 
4/5/6  
R 5/6 vs. 
R 4 
AFS 
 
1.56 
 
1.01 
- 
2.41 
 
31 
(46.2) 
16 
(23.9) 
20 
(29.9) 
Soga 
et al. 
2014 
(54) 
995 Rutherford 
4/5/6  
R 5 vs. R 
4 
Death 
 
2.3 
 
1.6 - 
3.3 
 
245 
(25) 
505 
(51) 
245 
(25) 
Spreen 
et al. 
2016 
(55) 
281 Rutherford 
4/5/6 
 
R 5/6 vs. 
R 4 
Major 
Amputation 
2.03 
 
1.28 
- 
3.21 
 
NR NR NR 
Table 2. Publications reporting unadjusted HR in Rutherford Category 5/6 vs Rutherford 
Category 4 patients. R4/5/6 = Rutherford Category 4/5/6. 
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Study N Event-free 
survivors 
(n) 
Observed 
AFS Rate 
Included 
Rutherford 
Categories 
Observed 
Proportion 
R4  
Observed 
Proportion 
R 5/6  
Imputed 
Proportion 
R 5/6  
Adjusted 
AFS Rate 
Brass et al 2006(56) 177 146 82.5% 4, 5, 6 NR NR 67.5% 59.6% 
Teraa et al. 2015(57) 79 66 83.5% 3, 4, 5, 6 31.6% 63.3% 63.3% 58.3% 
Dubsky et al. 2013(58) 22 10 45.5% 4, 5, 6 NR NR 67.5% 32.8% 
Iafrati et al. 2016(59) 34 22 64.7% 5 0.0% 100.0% 100.0% 64.7% 
Belch et al. 2011(60) 37 14 37.8% 4, 5, 6 NR NR 67.5% 27.3% 
Anghel et al. 2011(61) 14 3 21.4% 4,5 50.0% 50.0% 50.0% 13.5% 
Li et al. 2013(62) 29 22 75.9% 4, 5, 6 NR NR 67.5% 54.8% 
Benoit et al. 2011(63) 14 9 64.3% 4,5 50.0% 50.0% 50.0% 40.4% 
Gupta et al. 2013(64) 10 8 80.0% 4, 5, 6 20.0% 80.0% 80.0% 64.7% 
Szabo et al 2013(65) 10 4 40.0% 4, 5, 6 NR NR 67.5% 28.9% 
Belch et al. 2011(66) 259 196 75.7% 4, 5, 6 NR NR 67.5% 54.7% 
Losordo et al. 2012(67) 12 8 66.7% 4,5 41.7% 58.3% 58.3% 44.7% 
Nikol et al. 2008(68) 56 34 60.7% 4, 5, 6 NR NR 67.5% 43.9% 
Powell et al. 2012(69) 24 17 70.8% 4, 5, 6 NR NR 67.5% 51.2% 
Idei et al. 2011(70) 30 3 10.0% 4, 5, 6 27.0% 73.0% 73.0% 7.6% 
Pignon et al. 2017(71) 19 14 73.7% 4,5 35.0% 65.0% 65.0% 52.1% 
Meta-Analytic Average 60.0% Meta-Analytic Average 43.6% 
Table 3. Baseline CLI Status and 6-month adjusted and unadjusted AFS Rates 
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Study N Event-free 
survivors 
(n) 
Observed 
AFS Rate 
Included 
Rutherford 
Categories 
Observed 
Proportion 
R4  
Observed 
Proportion 
R 5/6  
Imputed 
Proportion 
R 5/6  
Adjusted 
AFS Rate 
Marston et al. 
2006(72) 
142 105 73.9% 4, 5, 6 NR NR 57.7% 49.3% 
Nikol et al. 2008(68) 56 27 48.2% 4, 5, 6 NR NR 57.7% 32.1% 
Belch et al. 2011(66) 259 173 66.8% 4, 5, 6 NR NR 57.7% 44.5% 
Losordo et al. 
2012(67) 
12 6 50.0% 4,5 41.7% 58.3% 58.3% 33.5% 
Teraa et al. 2015(57) 79 53 67.1% 3, 4, 5, 6 31.6% 63.3% 63.3% 46.8% 
Raval et al. 2014(73) 3 1 33.3% 4, 5, 6 NR NR 57.7% 22.2% 
Powell et al. 2012(69) 24 16 66.7% 4, 5, 6 NR NR 57.7% 44.4% 
Benoit et al. 2011(63) 14 9 64.3% 4,5 50.0% 50.0% 50.0% 40.4% 
Kibbe et al. 2016(74) 11 9 81.8% 4, 5 63.6% 36.4% 36.4% 46.7% 
Idei et al. 2011(70) 30 0 0.0% 4, 5, 6 27.0% 73.0% 73.0% 0.0% 
Szabo et al 2013(65) 10 4 40.0% 4, 5, 6 NR NR 57.7% 26.7% 
Pignon et al. 2017(71) 19 14 73.7% 4, 5 35.0% 65.0% 65.0% 52.1% 
Meta-Analytic Average 56.1% Meta-Analytic Average 36.8% 
Table 4. Baseline CLI Status and 12-month adjusted and unadjusted AFS Rates 
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Study 
N 
(sites) 
Limbs* 
Settings Classification 
Alexandrescu 
2011(75) 
25 (1) 
26* 
Retrospective single center Rutherford 5/6 
Arsenault 
2017(28) 
13 (3) 
14* 
Retrospective multicenter 
Rutherford 
4/5/6 
Djoric 
2011(76), 
2011(77), 
2012(78) 
30 (1) 
Prospective, randomized single 
center clinical trial 
Fontaine III/IV 
Engelke 
2001(79), 
Taylor 
1999(80) 
18 (1) Retrospective single center Fontaine III/IV 
Houlind 
2013(81) 
10 (1) Retrospective single center 
Fontaine 
III/IV** 
Lengua 
1995(82) 
25 (1) 
26* 
Retrospective single center Fontaine III/IV 
Matzke 
1999(83) 
14 (2) Retrospective multicenter Fontaine III/IV 
Mutirangura 
2011(29) 
26 (1) Prospective single center 
Fontaine 
III/IV** 
Sasajima 
2010(84) 
9 (1) Retrospective single center 
Rutherford 
5/6** 
Schreve 
2014(85) 
21 (1) Retrospective single center Fontaine IV 
Serra 2015(86) 9 (1) Prospective single center Rutherford 5/6 
Sheil 1977(24) 6 (1) Retrospective single center 
Fontaine 
III/IV** 
Sunar 2004(87) 
14 (1) 
15* 
Retrospective single center Fontaine IV** 
 Table 5.  Study Characteristics – Surgical Deep Vein Arterialization (DVA) 
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Study 
N (sites) 
Limbs* 
Settings Classification 
Gandini 2017(88) 5 (1) Retrospective single center Rutherford 5/6 
Gandini 2018(89) 9 (1) Retrospective single center Rutherford 6 
Kum 2017(25), 
Lichtenberg 
2017(90) 
7 (1) Prospective single center Rutherford 5/6 
Lichtenberg 
2016(91) 
11 (1) Retrospective single center 
Fontaine 
III/IV** 
Table 6. Study Characteristics – Percutaneous (endovascular) Deep Vein Arterialization 
(DVA) 
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Study 
Diabetes 
% (n/N) 
Hypertension 
% (n/N) 
Hyperlipidemia 
% (n/N) 
Coronary 
artery 
disease 
% (n/N) 
Chronic 
renal 
disease 
% (n/N) 
Current 
smokers 
% (n/N) 
Alexandrescu 2011(75) 100 (26/26) NR NR 88 (23/26) 42 (11/26) NR 
Arsenault 2017(28) 69 (9/13) NR NR NR 23 (3/13) NR 
Djoric 2011(76), 2011(77), 2012(78) 70 (21/30) 37 (11/30) 20 (6/30) 40 (12/30) 17 (5/30) NR 
Engelke 2001(79), Taylor 1999(80) 33 (6/18) NR NR NR NR NR 
Houlind 2013(81) 80 (8/10) 70 (7/10) NR NR 30 (3/10) 70 (7/10) 
Lengua 1995(82) 40 (10/25) 72 (18/25) NR 32 (8/25) NR 60 (14/25) 
Matzke 1999(83) 57 (8/14) 29 (4/14) 7 (1/14) 43 (6/14) 0 NR 
Mutirangura 2011(29) 85 (22/26) NR NR NR 19 (5/26) 19 (5/26) 
Sasajima 2010(84) NR NR NR NR 33 (3/9) NR 
Schreve 2014(85) 71 (15/21) 76 (16/21) 48 (10/21) NR 33 (7/21) 29 (6/21) 
Serra 2015(86) 100 (9/9) 78 (7/9) 78 (7/9) 67 (6/9) 56 (5/9) NR 
Sheil 1977(24) NR NR NR NR NR NR 
Sunar 2004(87) 100 (15/15) NR NR NR NR NR 
Simple Average 73% 60% 38% 54% 28% 45% 
Weighted Average 72% 58% 33% 53% 29% 40% 
Table 7.  Patient Characteristics – Surgical Deep Vein Arterialization (DVA). NR=not 
reported. 
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Diabetes 
(%, n/N) 
Coronary 
artery 
disease (%, 
n/N) 
Chronic renal 
disease (%, 
n/N) 
Gandini 2017(88) NR NR NR 
Gandini 2018(89) 100 (9/9) NR 100 (9/9) 
Kum 2017(25), Lichtenberg 
2017(90) 100 (7/7) 28 (2/7) 0 
Lichtenberg 2016(91) NR NR NR 
Table 8. Patient Characteristics – Percutaneous (endovascular) Deep Vein Arterialization 
(DVA) 
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Study 
N (sites) 
Limbs* 
Settings 
Tech. 
Success % 
(N) 
Peri-procedural < 30d 
Mortality % 
(N) 
Complications % (N) 
Alexandrescu 
2011(75) 
25 (1) 
26* 
Retrospective single 
center 
80 (21/26) 0 (0/25) 
26 (7/26) 
• transient cardiac 
deficiencies (2) 
• reversible contract induced 
renal failures (2) 
• compartmental syndrome 
and venous gangrene (1) 
• graft infection (1) 
• venous branch perforation 
(1) 
Arsenault 2017(28) 
13 (3) 
14* 
Retrospective 
multicenter 
93 (13/14) 7 (1/13) NR 
Djoric 2011(76), 
Djoric 2011(77), 
Djoric 2012(78) 
30 (1) 
Prospective, 
randomized single 
center 
NR 0 (0) 
47 (14) 
• wound infection (1) 
• bleeding (2) 
• graft thrombosis (6) 
• leg swelling (3) 
• pneumonia (1) 
• cardiac decompensation 
(2) 
Engelke 2001(79), 
Taylor 1999(80) 
18 (1) 
Retrospective single 
center 
NR 6 (1) 17 (3) 
• graft failure (3) 
Houlind 2013(81) 10 (1) 
Retrospective single 
center 
NR 0 (0) NR 
Lengua 1995(82) 
25 (1) 
26* 
Retrospective single 
center 
73 (19) NR 
35 (9) 
• graft failure (7) 
• venous branch perforation 
(2) 
Matzke 1999(83) 14 (2) 
Retrospective 
multicenter 
NR 0 (0) NR 
Mutirangura 
2011(29) 
26 (1) 
Prospective single 
center 
NR 4 (1) 
23 (6) 
• wound infection (2) 
• congestive cardiac failure 
(1) 
• incomplete destruction of 
valves (3) 
Sasajima 2010(84) 9 (1) 
Retrospective single 
center 
78 (7) 0 (0) 22 (2) 
• graft failure (2) 
Schreve 2014(85) 21 (1) 
Retrospective single 
center 
NR 5 (1) 
14 (3) 
• bleeding (1) 
• graft thrombosis (1) 
• wound infection (1) 
Serra 2015(86) 9 (1) 
Prospective single 
center 
NR 0 (0) NR 
Sheil 1977(24) 6 (1) 
Retrospective single 
center 
83 (5) 0 (0) 16 (1) 
• myocardial infarction (1) 
Sunar 2004(87) 
14 (1) 
15* 
Retrospective single 
center 
80 (12) 7 (1) NR 
Average 81% 2.4% 25%* 
Weighted Average 80% 2.6% 27%* 
Table 8. Peri-procedural Outcomes for Surgical Deep Vein Arterialization (DVA). 
*=average rate of any reported complication 
46 
 
  
Study 
N (sites) 
Limbs* 
Tech. 
Success % 
(N) 
Transcutaneous O2 
Pressure 
Peri-procedural 
Mortality % (N) Complications % (N) 
Gandini 2017(88) 5 (1) 100 (5) 
• Before: 16.7 ± 1.4 
mmHg 
• After: 45.7 ± 1.2 
mmHg 
0 (0)  NR 
Gandini 2018(89) 9 (1) 78 (7) 
• Before: 7.3 ± 2.2 
mmHg 
• After: 37.1 ± 17 
mmHg 
0 (0) 0 (0) 
Kum 2017(25), 
Lichtenberg 2017(90) 
7 (1) 100 (7) 
• Before: 8 mmHg 
(IQR 4-17) 
• After: 61 mmHg (IQR 
50-76) 
• Value was >40 
mmHg in 83% (5/6) 
• At time of wound 
healing in 5 patients: 
median was 59 mmHg 
(IQR 36-67 mmHg) 
0 (0) 29 (2) 
• adverse cardiac events (2) 
Lichtenberg 2016(91) 11 (1) NR 
• tcPO2 has increased 
in all patients and 
stayed above 40mmHg 
passed the 6m and 12m 
checks 
0 (0) 18 (2) 
• adverse cardiac events (2) 
Average 93%  0% 16%* 
 91%  0% 15%* 
 Table 9. Peri-procedural Outcomes for Percutaneous (endovascular) Deep Vein 
Arterialization (DVA). *=average rate of any reported complication 
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Study 
N (sites) 
Limbs* 
Settings 
Postprocedural ≥ 30d 
Survival % (N) 
Limb Salvage 
% (N) 
Cumulative 
Patency % (N) 
Alexandrescu 
2011(75) 
25 (1) 
26* 
Retrospective single 
center 
12m: 
93 (23/25) 
24m: 
67 (17/25) 
36m: 
54 (14/25) 
12m, 24m, 36m: 
73 (19/26) 
12m: 
66 (17/26) 
24m: 
60 (16/26) 
36m: 
48 (12/26) 
 
Arsenault 2017(28) 
13 (3) 
14* 
Retrospective 
multicenter 
NR 
mean f/u time 
NR: 
71 (10/14) 
30d: 
82 (11/14) 
Djoric 2011(76), 
Djoric 2011(77), 
Djoric 2012(78) 
30 (1) 
Prospective, 
randomized single 
center 
mean f/u time 6.13 
± 4.32m: 
97 (29) 
mean f/u time 
6.13 ± 4.32m: 
83 (25) 
mean f/u time    6.13 
± 4.32m: 
83 (25) 
Engelke 2001(79), 
Taylor 1999(80) 
18 (1) 
Retrospective single 
center 
mean f/u time 25m 
(range 9-48m) 
94 (17) 
overall: 
83 (15) 
2 years: 
75 (14) 
primary patency: 
66 (12) 
secondary patency: 
72 (13) 
Houlind 2013(81) 10 (1) 
Retrospective single 
center 
mean f/u time 
133.3d (range 
1-342d) 
90 (9) 
mean f/u time 
133.3d (range 
1-342d) 
30 (3) 
NR 
Lengua 1995(82) 
25 (1) 
26* 
Retrospective single 
center 
mean f/u time 41m 
(range 3-132m) 
52 (13) 
calculated as the 
inverse of mortality 
mean f/u time 
41m (range 
3-132m) 
81 (21) 
calculated as the 
inverse of the rate 
of amputation 
mean f/u time 41m 
(range 3-132m) 
72 (19) 
Matzke 1999(83) 14 (2) 
Retrospective 
multicenter 
30d: 
100 (14) 
6m: 
92 (13) 
12m: 
92 (13) 
30d: 
86 (12) 
6m: 
57 (8) 
12m: 
57 (8) 
NR 
Mutirangura 
2011(29) 
26 (1) 
Prospective single 
center 
6m: 
96 (25) 
12m: 
85 (22) 
24m: 
85 (22) 
6m, 12m, 24m: 
76 (20) 
6m: 
72 (19) 
12m: 
59 (15) 
24m: 
49 (13) 
Sasajima 2010(84) 9 (1) 
Retrospective single 
center 
median f/u time 
12m (range 
2-36m) 
89 (8) 
median f/u time 
12m (range 
2-36m) 
78 (7) 
primary patency: 
44 (4) 
secondary patency: 
56 (5) 
Schreve 2014(85) 21 (1) 
Retrospective single 
center 
mean f/u time NR: 
76 (16) 
calculated as the 
inverse of mortality 
mean f/u time 
NR: 
53 (11) 
mean f/u time NR: 
71 (15) 
Serra 2015(86) 9 (1) 
Prospective single 
center 
12m: 
100 (9) 
24m: 
89 (8) 
36m: 
78 (7) 
12m: 
100 (9) 
24m: 
89 (8) 
36m: 
89 (8) 
NR 
Sheil 1977(24) 6 (1) 
Retrospective single 
center 
mean f/u time NR: 
67 (4) 
mean f/u time 
NR: 
50 (3) 
NR 
Sunar 2004(87) 
14 (1) 
15* 
Retrospective single 
center 
mean f/u time 20m 
(range 1-62m): 
79 (11) 
5y (calc. by 
Kaplan-Meier 
method): 
56 (8) 
mean f/u time 
20m (range 
1-62m): 
73 (11) 
mean f/u time 20m 
(range 1-62m): 
80 (12) 
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 Table 10.  Medium-term Outcomes for Surgical Deep Vein Arterialization (DVA) 
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Study 
N (sites) 
Limbs* 
Postprocedural 
Survival % (N) 
Limb Salvage % 
(N) 
Cumulative Patency % 
(N) 
Gandini 2017(88) 5 (1) 
mean f/u time NR: 
100 (5) 
mean f/u time NR: 
80 (4) 
NR 
Gandini 2018(89) 9 (1) 
mean f/u time NR: 
100 (9) 
mean f/u time NR: 
56 (5) 
NR 
Kum 2017(25), 
Lichtenberg 2017(90) 
7 (1) 
mean f/u time NR: 
57 (4) 
calculated as the inverse of 
mortality 
12m: 
71 (5) 
NR 
Lichtenberg 2016(91) 11 (1) 
mean f/u time NR: 
72 (8) 
mean f/u time NR: 
100 (11) 
NR 
Average  82% 77%  
Weighted average  76% 78%  
 Table 11. Medium Term Outcomes for Percutaneous (endovascular) Deep Vein 
Arterialization (DVA)
50 
 
 
Figure 1. 
Records identified through 
database searching 
(n =1353) 
S
cr
ee
n
in
g
 
In
cl
u
d
ed
 
E
li
g
ib
il
it
y
 
Id
en
ti
fi
ca
ti
o
n
 Additional records identified 
through other sources 
From primary eligible articles (n 
= 11)  
Records after duplicates removed 
(n =  1142) 
Records screened 
(n =  1142) 
Records excluded 
(n =  1089) 
Full-text articles 
assessed for eligibility 
(n =  41), 39 identified 
through database 
searching 
Full-text articles excluded, 
with reasons 
(n=1) full-text not available 
(n=2) incorrect follow-up time 
for endpoints of interest 
(n=1) no placebo cohort 
(n=1) included revascularized 
patients + incorrect follow-up 
time points Studies included in 
qualitative synthesis 
(n =  36) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =  23 ) 6-month AFS 
(n = 19 ) 12-month AFS 
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Figure 2. Risk-adjusted 6-month AFS Rates in patients with no-option CLI.  
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Figure 3. Risk-adjusted 12-month AFS Rates in patients with no-option CLI. 
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Supplemental Materials 
Supplemental: 
Search 
ID 
Search Terms 
1.1 peripheral artery disease OR peripheral occlusive disease OR peripheral 
vascular disease OR peripheral angiopathy OR atherosclerosis OR 
arteriosclerosis OR intermittent claudication OR arterial occlusive 
diseases OR ischemia OR ischaemia OR ischemic OR ischaemic OR 
"circulation disorder*" OR "circulation failure*" OR "circulation 
disturbance*" OR "circulatory disorder*" OR "circulatory failure*" OR 
"circulatory disturbance* OR ((artery OR vascular OR vein OR 
peripheral) AND (stenosis OR lesion OR blockage OR occlusion OR 
obstruction))  
1.2 leg OR lower extremity OR foot OR feet OR toes OR digits OR knees OR 
ankle OR calf 
1.3 mortality OR survival OR amputation OR amputation-free survival OR 
limb loss OR wound healing OR ulcer healing  
1.4 natural history OR placebo OR critical OR severe OR untreated OR 
unreconstructed OR nonreconstructable OR unintervened OR unsuitable 
for surgery OR unsuitable for revascularization OR no-option 
1.5 [study type] controlled OR randomized OR meta-analysis OR systematic 
review OR guideline OR case control OR follow-up OR cohort OR 
longitudinal OR prospective OR retrospective OR observational OR 
comparative OR clinical trial OR evaluation OR validation OR 
experimental OR evaluation 
1.6 1.1 AND 1.2 AND 1.3 AND 1.4 AND 1.5  
1.7 1.8 AND humans AND English 
Supplemental Table 1. Search Terms For 6- and 12-month Outcomes. This table contains an abridged 
search strategy used for OVID querying Medline, EMBASE, and the Cochrane Database of Systematic 
Reviews (CDSR) 
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Search 
ID 
Search Terms 
2.1 “amputation-free survival” or “AFS” or “death or major amputation” or 
“death or amputation” or “major amputation” or “mortality” or “death” or 
“all-cause” or “limb salvage”  
2.2 “Rutherford” or “Fontaine” 
2.3 2.1 and 2.2 
2.4 “CLI” or “critical limb ischemia” or “PVD” or “peripheral vascular disease” 
or “rest-pain” or “peripheral art*” or “ischemia” or “lower extremity 
ischemia” or “lower limb ischemia” 
2.5 2.3 and 2.4 
2.6 “*ratio” or “*variate” or “predic*” or “hazard” or “Cox proportional hazard*”  
2.7 2.6 AND humans AND English 
Supplemental Table 2. Search Terms For Risk-Adjustment. This table contains an abridged search 
strategy used for OVID querying Medline, EMBASE, and the Cochrane Database of Systematic Reviews 
(CDSR)
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Grade Category Clinical criteria Objective criteria 
0 0 
Asymptomatic-no 
hemodynamically significant 
occlusive disease Normal treadmill or reactive hyperemia test 
 1 Mild claudication 
Completes treadmill exercise; AP after 
exercise > 50 mmHg but at least 20 mm Hg 
lower than resting value 
I 2 Moderate claudication Between categories 1 and 3 
 3 Severe claudication 
Cannot complete standard treadmill exercise, 
and AP after exercise < 50 mm Hg 
II 4 ischmic rest pain 
Resting AP < 40 mm Hg, flat or barely 
pulsatile ankle or metatarsal PVR; TP < 30 
mm Hg 
III 5 
Minor tissue loss-nonhealing ulcer, 
focal gangrene with diffuse pedal 
ischemia 
Resting AP < 60 mm Hg, ankle or metatarsal 
PVR flat or barely pulsatile; TP < 40 mm Hg 
 6 
Major tissue loss-extending above 
TM level, functional food no longer 
salvageable Same as category 5 
Supplemental Table 3. Rutherford categorization based on reported objective criteria 
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Study N 
Event-
free 
survivors 
(n) 
Event-
free Rate 
Last 
enrolled 
patient 
Rutherford 
Category 
Proportion 
with R4 
(FIII) 
Proportion 
with R 5/6 
(FIV) 
IMPUTED 
Proportion 
with R 5/6 
(FIV) Adjusted 
Lepantalo et al. 
1996 
105 40 38.1% Jul-1992 4, 5, 6 NR NR 67.5% 27.5% 
Boccalon et al. 
2000 (Cohort 
A) 
62 32 51.6% Jul-2000 4, 5, 6 NR NR 67.5% 37.3% 
Brass et al. 
2006 
177 146 82.5% Sep-2005 4, 5, 6 NR NR 67.5% 59.6% 
Teraa et al. 
2015 
79 66 83.5% Jun-2012 3, 4, 5, 6 31.6% 63.3% 63.3% 58.3% 
Dubsky et al 
2013 
22 10 45.5% Mar-2012 4, 5, 6 NR NR 67.5% 32.8% 
Iafrati et al. 
2016 
34 22 64.7% Jul-2016 5 0.0% 100.0% 100.0% 64.7% 
Belch et al. 
2011 
37 14 37.8% Jul-2009 4, 5, 6 NR NR 67.5% 27.3% 
Jivegard et al. 
1995 
26 16 61.5% Jul-1995 4, 5, 6 NR NR 67.5% 44.5% 
Klomp et al. 
1999 
60 34 56.7% Jul-1996 4, 5, 6 NR NR 67.5% 40.9% 
Lund et al. 
1999 
28 10 35.7% Jun-1999 4, 5, 6 NR NR 67.5% 25.8% 
Anghel et al. 
2011  
14 3 21.4% Mar-2011 4,5 50.0% 50.0% 50.0% 13.5% 
Li et al. 2013 29 22 75.9% Jan-2010 4,5,6 NR Minimum of 
58.6 
67.5% 54.8% 
Benoit et al. 
2011 
14 9 64.3% Aug-2011 4,5 50.0% 50.0% 50.0% 40.4% 
Gupta et al. 
2013 
10 8 80.0% Jul-2012 4,5,6 20.0% 80.0% 80.0% 64.7% 
UK Severe 
Limb Ischemia 
71 30 42.3% Jul-1991 4,5,6 NR NR 67.5% 30.5% 
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Study N 
Event-
free 
survivors 
(n) 
Event-
free Rate 
Last 
enrolled 
patient 
Rutherford 
Category 
Proportion 
with R4 
(FIII) 
Proportion 
with R 5/6 
(FIV) 
IMPUTED 
Proportion 
with R 5/6 
(FIV) Adjusted 
Study Group 
1991 
Pignon et al. 
2017 
19 14 73.7% Jul-2009 4,5 35.0% 65.0% 65.0% 52.1% 
Szabo et al 
2013 
10 4 40.0% Oct-2013 4, 5, 6 NR NR 67.5% 28.9% 
Belch et al. 
2011 
259 199 76.8% Jul-2009 5.6 NR NR 67.5% 55.5% 
Losordo et al. 
2012 
12 8 66.7% Apr-2010 4,5 41.7% 58.3% 58.3% 44.7% 
Nikol et a. 2008 56 34 60.7% Apr-2004 5, 6 NR NR 67.5% 43.9% 
Powell et al. 
2012 
24 17 70.8% Mar-2010 5, 6 NR NR 67.5% 51.2% 
Idei et al. 2011 30 3 10.0% Dec-2008 4, 5, 6 27.0% 73.0% 73.0% 7.6% 
Ubbink et al. 
1999 
60 35 58.3% May-1994 4, 5, 6 NR NR 67.5% 42.1% 
Supplemental Table 4.  Characteristics of Studies Reporting Amputation-Free Survival at 6-months. R4/5/6=Rutherford Category 4/5/6. 
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Study N 
Event-free 
survivors 
(n) 
Event-
free Rate 
Last 
enrolled 
patient 
Rutherford 
Category 
Proportion 
with R4 
(FIII) 
Proportion 
with R 5/6 
(FIV) 
IMPUTED 
Proportion 
with R 5/6 
(FIV) Adjusted 
Lepantalo et al. 
1996 
105 30 28.6% Jul-1992 4, 5, 6 NR NR 57.7% 19.0% 
Marston et al. 
2006 
142 105 73.9% Mar-2005 5,6 NR NR 57.7% 49.3% 
Boccalon et al. 
2000 (Cohort 
B) 
207 133 64.3% Jul-2000 4,5,6 NR NR 57.7% 42.8% 
Nikol et al. 
2008 
56 27 48.2% Apr-2004 5,6 NR NR 57.7% 32.1% 
Belch et al. 
2011 
259 173 66.8% Jul-2009 5,6 NR NR 57.7% 44.5% 
Losordo et al. 
2012 
12 6 50.0% Apr-2010 4,5 41.7% 58.3% 58.3% 33.5% 
Teraa et al. 
2015 
79 53 67.1% Jun-2012 3, 4, 5, 6 31.6% 63.3% 63.3% 46.8% 
Belch et al. 
2011 
37 11 29.7% Feb-1994 4, 5, 6 NR NR 57.7% 19.8% 
Jivegard et al. 
1995 
26 13 50.0% Jul-1995 4, 5, 6 NR NR 57.7% 33.3% 
Lund et al. 
1999 
28 6 21.4% Jun-1999 4, 5, 6 NR NR 57.7% 14.3% 
Raval et al. 
2014 
3 1 33.3% Aug-2012 4, 5, 6 NR NR 57.7% 22.2% 
Powell et al. 
2012 
24 16 66.7% Mar-2010 4, 5, 6 NR NR 57.7% 44.4% 
Amann et al. 
2003 
39 18 44.9% Jan-2002 4, 5, 6 NR NR 57.7% 29.9% 
Benoit et al. 
2011 
14 9 64.3% Aug-2011 4,5 50.0% 50.0% 50.0% 40.4% 
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Study N 
Event-free 
survivors 
(n) 
Event-
free Rate 
Last 
enrolled 
patient 
Rutherford 
Category 
Proportion 
with R4 
(FIII) 
Proportion 
with R 5/6 
(FIV) 
IMPUTED 
Proportion 
with R 5/6 
(FIV) Adjusted 
Kibbe et al. 
2016 
11 9 81.8% Jul-2012 4, 5 63.6% 36.4% 36.4% 46.7% 
Idei et al. 2011 30 0 0.0% Dec-2008 4,5,6 27.0% 73.0% 73.0% 0.0% 
Pignon et al 
2017 
19 14 73.7% 
Jul-2009 
4, 5 35.0% 65.0% 65.0% 52.1% 
Szabo et al 
2013 
10 4 40.0% Oct-2013 4, 5, 6 NR NR 57.7% 26.7% 
Ubbink et al. 
1999 
60 22 36.7% May-1994 4, 5, 6 NR NR 57.7% 24.4% 
Supplemental Table 5.  Characteristics of Studies Reporting Amputation-Free Survival at 12-months. R4/5/6=Rutherford Category 4/5/6. 
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Search ID Search Terms 
1.1 critical limb ischemia OR critical limb ischaemia OR peripheral vascular disease OR Rutherford OR Fontaine OR claudication 
OR rest pain OR gangrene OR ulcers OR tissue loss 
1.2 leg OR lower extremity OR lower limb OR foot OR feet OR toes OR digits OR knees OR ankle OR calf OR tibial OR pedal 
OR plantar OR popliteal OR femoral 
1.3 open OR surgical OR endovascular OR percutaneous 
1.4 venous arterialization OR venous arterilization OR venous arterialisation OR arteriovenous fistula OR arterviovenous fistulae 
OR AVF OR AV fistula OR AV fistulae OR vein arterialization or vein arterialisation OR in situ bypass OR in situ vein bypass 
OR in situ venous bypass 
1.5 1.1 AND 1.2 AND 1.3 AND 1.4 
1.6 Remove duplicates from 1.5 
1.7 1.6 AND English 
Supplemental Table 6. Deep Vein Arterialization Search Terms 
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Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting 
Other 
bias 
Lepantalo et 
al. 1996 
- - - - + + + 
Boccalon et 
al. 2000 
(Cohort A) 
+ + + + + + + 
Brass et al 
2006 
+ + + + + + + 
Teraa et al. 
2015 
+ + + + + + + 
Dubsky et al. 
2013 
- - - - + + + 
Iafrati et al. 
2016 
+ + + + + + + 
Belch et al. 
2011 
+ + + + + + + 
Jivegard et. 
al 1995 
+ - - ? + + + 
Klomp et al. 
1999 
+ - - ? + + + 
Lund et al. 
1999 
- - - - ? + ? 
Anghel et al. 
2011  
+ + + + + + + 
Li et al. 2013 
+ + + - + + + 
68 
 
 
  
Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting 
Other 
bias 
Benoit et al. 
2011 
+ + + + + + + 
Gupta et al. 
2013 
+ + + + + + + 
Bliss et al. 
1991 
+ + + + + + + 
Pignon et al. 
2017 
+ + + + + + + 
Szabo et al 
2013 
+ + ? ? + + ? 
Belch et al. 
2011 
+ + + + + + + 
Losordo et al. 
2012 
+ + + + + + + 
Nikol et al. 
2008 
+ + + + + + + 
Powell et al. 
2012 
+ + + + + + + 
Idei et al. 
2011 
- - ? ? + + ? 
Ubbink et al. 
1999 
+ - ? ? + + ? 
Marston et al. 
2006 
- - - - + + + 
Raval et al. 
2014 
+ + + + + + + 
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Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting 
Other 
bias 
Amann et al. 
2003 
- - - - + + ? 
Kibbe et al. 
2016 
+ + + + + + + 
Supplemental Table 6. Risk of Bias Assessment. + = low-risk, - = high-risk, ? = uncertain risk. 
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Supplemental Figure 1. Flow diagram for supplemental literature search. 
 
